Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P30260
UPID:
CDC27_HUMAN
Alternative names:
Anaphase-promoting complex subunit 3; CDC27 homolog; H-NUC
Alternative UPACC:
P30260; G3V1C4; Q16349; Q96F35
Background:
Cell division cycle protein 27 homolog (CDC27) is a crucial component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is pivotal in controlling progression through mitosis and the G1 phase of the cell cycle by mediating ubiquitination and subsequent degradation of target proteins. It primarily facilitates the formation of 'Lys-11'-linked polyubiquitin chains, with lesser activity towards 'Lys-48'- and 'Lys-63'-linked chains.
Therapeutic significance:
Understanding the role of Cell division cycle protein 27 homolog could open doors to potential therapeutic strategies.